{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:47:55Z","timestamp":1786996075715,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.psym.2013.08.008","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T20:45:40Z","timestamp":1382042740000},"page":"29-36","source":"Crossref","is-referenced-by-count":99,"title":["Psychotropic-Induced Hyperprolactinemia: A Clinical Review"],"prefix":"10.1016","volume":"55","author":[{"given":"Adnan","family":"Ajmal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadine","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psym.2013.08.008_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum Psychopharmacol"},{"issue":"1 Suppl","key":"10.1016\/j.psym.2013.08.008_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psym.2013.08.008_bib4","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/157488711793980138","article-title":"Recent clinical aspects of hyperprolactinemia induced by antipsychotics","volume":"6","author":"Milano","year":"2011","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.psym.2013.08.008_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperprolactinaemia caused by antipsychotic drugs","volume":"324","author":"Wieck","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.psym.2013.08.008_bib7","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psym.2013.08.008_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.genhosppsych.2006.03.003","article-title":"Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate","volume":"28","author":"Foley","year":"2006","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib9","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.psym.2013.08.008_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients","volume":"66","author":"Melkersson","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"1 Suppl","key":"10.1016\/j.psym.2013.08.008_bib11","first-page":"14","article-title":"Asenapine: a clinical overview","volume":"72","author":"Potkin","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.psym.2013.08.008_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","article-title":"Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder","volume":"43","author":"Schoemaker","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1176\/appi.ajp.162.10.1984-a","article-title":"An update of fast-off dopamine D2 atypical antipsychotics","volume":"162","author":"Seeman","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"Arakawa","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","article-title":"Prolactinemia is uncoupled from central D2\/D3 dopamine receptor occupancy in amisulpride treated patients","volume":"175","author":"Bressan","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"1 Suppl","key":"10.1016\/j.psym.2013.08.008_bib19","first-page":"S38","article-title":"Flupenthixol\u2014a partial atypical neuroleptic?","volume":"68","author":"Kuhn","year":"2000","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.1016\/j.psym.2013.08.008_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063574","article-title":"Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels","volume":"46","author":"Schlosser","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psym.2013.08.008_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management","volume":"24","author":"Coker","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psym.2013.08.008_bib22","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4088\/JCP.v67n0612","article-title":"Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine","volume":"67","author":"Papakostas","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","article-title":"A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics","volume":"26","author":"Serretti","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.psym.2013.08.008_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.924","article-title":"Sexual dysfunction in schizophrenia: focus on recent evidence","volume":"23","author":"Baggaley","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psym.2013.08.008_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/JCP.0b013e31819c76e9","article-title":"Sexual dysfunction, depression, and the impact of antidepressants","volume":"29","author":"Kennedy","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"4 Pt 2","key":"10.1016\/j.psym.2013.08.008_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0029-7844(98)00175-6","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.psym.2013.08.008_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","article-title":"Osteoporosis and fracture risk in people with schizophrenia","volume":"25","author":"Kishimoto","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1210\/jc.75.3.692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.psym.2013.08.008_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.psym.2013.08.008_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03345523","article-title":"Prevalence of osteopenia in men with prolactinoma","volume":"28","author":"Naliato","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.psym.2013.08.008_bib32","first-page":"933","article-title":"Prevalence and magnitude of osteopenia in patients with prolactinoma","volume":"26","author":"Kayath","year":"1993","journal-title":"Braz J Med Biol Res"},{"issue":"Pt 4","key":"10.1016\/j.psym.2013.08.008_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","article-title":"A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?","volume":"47","author":"Bushe","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.psym.2013.08.008_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: a population-based cohort study","volume":"165","author":"Berinder","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.psym.2013.08.008_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.psym.2013.08.008_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr Pract"},{"key":"10.1016\/j.psym.2013.08.008_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib38","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psym.2013.08.008_bib40","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib41","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psym.2013.08.008_bib42","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.psym.2013.08.008_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","article-title":"Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study","volume":"64","author":"Lee","year":"2010","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318213001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318213001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T19:37:39Z","timestamp":1564515459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318213001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0033318213001667"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2013.08.008","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}